Outline. Definitions Background Objectives Methodology Results and Discussion Conclusion and Recommendations
|
|
- Abel Spencer
- 5 years ago
- Views:
Transcription
1 An Economic Evaluation of Salt Reduction as a Population Based Intervention for the Prevention of Coronary Heart Disease in Four Eastern Mediterranean Countries (Palestine, Syria, Tunisia, Turkey) Cost Effectiveness Study H Mason, A Shoaibi, R Ghandour, M O Flaherty, S Capewell, R Khatib, S Jabr, B Unal, K Sözmen, C Arfa, H Ben Romdhane, F Fouad, R Al-Ali, A Husseini, and the MedCHAMPS project team
2 Outline Definitions Background Objectives Methodology Results and Discussion Conclusion and Recommendations
3 Definitions - Economic evaluation: an analytical approach that examines the costs and consequences of alternative programs in order to inform decisions about the allocation of scarce resources. - Cost effectiveness analysis: a type of economic evaluation used to determine the best use of money available for health care. It compares different kinds of interventions with similar, but not identical effects on the basis of the cost per unit effect achieved, usually (cost/lyg).
4 Background Cardiovascular disease (CVDs) is number one cause of death worldwide. Coronary heart diseases (CHDs) as one of the CVDs pose a growing challenge in the world. It is important to make recommendations for cost-effective policy initiatives, both within and outside the health sector, likely to reduce the burden of CHD mortality and morbidity. A major modifiable risk factor for CHD is dietary salt intake International past experiences have proved that reducing salt intake in communities is possible and is one of the most costeffective and affordable public health interventions.
5 Background There is direct a dose response relationship between salt intake and blood pressure Reducing salt intake by 5 g à 17% of cardiovascular events worldwide Reducing blood pressure by 10 mmhg à CHD events by 22% Recommended Salt Intake: 5 g/person/day (WHO) Global level: 9-12 g/person/day In Palestine, Syria and Tunisia: 14 g/person/day In Turkey : 18 g/ Person /day
6 Aim To assess the cost-effectiveness of population-based interventions aiming to reduce salt intake and hence prevent coronary heart diseases diseases in 4 Eastern Mediterranean countries (Palestine, Syria, Tunisia and Turkey) Consequences (Outputs) Costs (Inputs)
7 Methodology Step 1: Identify SALT REDUCTION polices at the population level. Step 2: Identify and quantify the cost of implementing these policies Step 3 :Identify and quantify effectiveness measures: life years gained (LYG) Step 4: Evaluate the cost effectiveness measures (Incremental Cost Effectiveness Ratio - ICER) of each policy compared with doing nothing
8 Methodology-cont. Time frame for the analysis: 10 years Future costs were discounted by 3% The analysis was done from the societal perspective with reference to other perspectives such as industry and government Sensitivity analysis was performed using minimum and maximum costs Costs were quantified using the international$ (PPP) to allow comparison
9 Methodology-cont. Step1: identify the policies 3 main Salt Reduction Policies were identified: Population-wide information campaigns (Health Promotion) Declaration of salt content in processed food, through labeling Decrease in salt content of processed foods (Reformulation)
10 Step 1-cont. Methodology-cont. 6 different alternatives were identified: 1. Population-wide information campaigns 2. Declaration of salt content in processed food (labeling) 3. Decrease in salt content of processed foods (Reformulation) 4. Reformulation and labeling 5. Reformulation and health promotion 6. ALL THREE (Health promotion, labeling and reformulation) All alternatives were compared to doing nothing scenario
11 Methodology-cont. Step 2: Identifying Costs 1. Cost of policy Cost of implementing each policy Cost of illness on health sector 2. Cost of doing nothing (baseline) Cost of illness on the health sector (burden of the disease) Indirect Cost: cost of illness on the society (productivity loss) The incremental cost was calculated as the difference between these 2 costs.
12 Methodology- cont. Step3: Iden4fy effec4veness (LYG) Life years gained (LYG) for each policy: The incremental years gained compared to the baseline Salt Reduction Policy reduces salt intake (source: literature) Reduction in Salt intake will reduce the SBP on the population level (source: literature) Reduction in SBP will reduce CHD attributable deaths (source: Palestinian IMPACT model) Outcome measured in LYG
13 Results Palestinian Results
14 Palestinian Results Policy Total Cost (PPP) Discounted Total Cost (PPP) Incremental cost over the baseline (PPP) Discounted incremental cost over the baseline (PPP) Life Years Gained Over Baseline ICER Baseline 354,719, ,616,109 Health Promotion 344,231, ,781,187-10,487,653-6,834, Labelling 341,136, ,165,868-13,582,543-9,450, Reformulation 350,715, ,741,346-4,007, , Reformulation + Labelling Reformulation + Health Promotion All 3 Policies together 348,382, ,777,907-6,337,103-1,838, ,683, ,028,495-6,036,400-1,587, ,638, ,921,135-12,081,323-6,694,
15 Pales4ne Discounted Cost Saving Against the Baseline min costs Best Es4mate max costs Health Promo4on Labelling Reformula4on Reformula4on + Labelling Reformula4on + Health Promo4on All 3 Policies together LYG ,398 1,398 2,682 ICER 132
16 Syria - Disoucnted cost Saving against the baseline min costs Best Es4mate max costs Health Promo4on Labelling Reformula4on Reformula4on + Labelling Reformula4on + Health Promo4on All 3 Policies together LYG 5,679 11,192 11,192 16,543 16,543 31,674 ICER
17 Tunisia : Cost Saving against Baseline min costs Best Es4mate max costs 450,000, ,000, ,000, ,000, ,000, ,000, ,000, ,000,000 50,000, ,000, ,000,000 Health Promo8on Labelling Reformula8on Reformula8on + Reformula8on + Labelling Health Promo8on All 3 Policies together LYG 1,151 2,272 2,272 3,361 3,361 6,455 ICER 5377
18 Turkey - Cost Saving against the baseline min costs Best Es8mat max costs 2E E E E E+09 1E Health Promo4on Labelling Reformula4on Reformula4on + Labelling Reformula4on + Health Promo4on All 3 Policies together LYG 68, , , , , ,439
19 Conclusion and Recommendations Decreasing salt intake reduces the long-term risk of CHD events. In the opt, as well other study countries, most of the population based interventions to reduce salt intake is not only cost effective but also cost saving. A combination of health education and cooperation with the food industry to label and reduce salt content would save both money and lives. Intersectoral collaboration is highly important in reducing the burden of CHDs
20 Acknowledgment The research leading to these results has received funding from the European Community s Seventh Framework Programme (FP7/ ) under grant agreement n the MedCHAMPS project We would like to thank all people at the clinics and the hospitals in as well as the industry union who helped us in collecting the data and making this analysis possible.
Glasgow Caledonian University
ResearchOnline@GCU Glasgow Caledonian University A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries Mason, Helen; Shoaibi,
More informationView on Existing Models, Applicability and Limitations: Public Health Perspective
The European Commission s science and knowledge service Joint Research Centre View on Existing Models, Applicability and Limitations: Public Health Perspective Jan Wollgast ILSI Europe Workshop Identifying
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationImpact of Risk Factor Modifications on Coronary Heart Disease Mortality in Turkish Adults for 2025
Faculty of Health Sciences Impact of Risk Factor Modifications on Coronary Heart Disease Mortality in Turkish Adults for 2025 Authors: Ceyda Sahan 1, Kaan Sozmen 2, Belgin Unal 1, Julia Critchley 3 1 Department
More informationEConDA Economics of Chronic Diseases
EConDA Economics of Chronic Diseases www.econdaproject.eu Funding from the European Union in the framework of the Health Programme Abbygail Jaccard Deputy Director of Public Health Modelling UK Health
More informationMeeting the 2025 salt and raised blood pressure reduction targets
Meeting the 2025 salt and raised blood pressure reduction targets Dr Timothy Armstrong Coordinator Department of Prevention of Noncommunicable Diseases Leading risk factors for global mortality Source:
More informationBasic Economic Analysis. David Epstein, Centre for Health Economics, York
Basic Economic Analysis David Epstein, Centre for Health Economics, York Contents Introduction Resource use and costs Health Benefits Economic analysis Conclusions Introduction What is economics? Choices
More informationCost-effectiveness of a community anti-smoking campaign targeted at a high risk group in London Stevens W, Thorogood M, Kayikki S
Cost-effectiveness of a community anti-smoking campaign targeted at a high risk group in London Stevens W, Thorogood M, Kayikki S Record Status This is a critical abstract of an economic evaluation that
More informationRESCAP-MED SIXTH NEWSLETTER
1 RESCAP-MED SIXTH NEWSLETTER What is RESCAP-MED? RESCAP-MED aims to build research capacity for public health in countries around the eastern and southern Mediterranean. Its purpose is to develop research
More informationWorkshop on Health Statistics. Annotations for the Agenda. Venue : Union internationale des chemins de fer (UIC P) Centre de conférence
Social Statistics Sector Workshop on Health Statistics Annotations for the Agenda Venue : Union internationale des chemins de fer (UIC P) Centre de conférence 16, rue Jean Rey, 75015 PARIS Metro: Bir Hakeim
More informationIntroduction to Finnish NCD Prevention. PREVENTION OF NONCOMMUNICABLE DISEASES SEMINAR, Helsinki
Introduction to Finnish NCD Prevention PREVENTION OF NONCOMMUNICABLE DISEASES SEMINAR, Helsinki 14.3.2011 28/03/2011 Pekka Puska, Director General 2 Global Health Burden Estimated global deaths by cause,
More informationWHO global response to salt reduction strategies
WHO global response to salt reduction strategies Dr Godfrey C Xuereb Team Leader Population-based Prevention Team SPP Unit Prevention of Noncommunicable Diseases Department The World Health Organization
More informationReduction in salt consumption in Europe: a preventive and economic imperative Francesco P Cappuccio MD MSc DSc FRCP FFPH FBHS FAHA
Reduction in salt consumption in Europe: a preventive and economic imperative Francesco P Cappuccio MD MSc DSc FRCP FFPH FBHS FAHA Professor of Cardiovascular Medicine & Epidemiology Head, WHO Collaborating
More informationRole of UN Agencies in Achieving the Sustainable Development Goals (SDG 3.4)
Role of UN Agencies in Achieving the Sustainable Development Goals (SDG 3.4) Oyere K. Onuma, MD MSc Medical Officer, Cardiovascular Diseases Management of Noncommunicable Diseases, Disability, Violence
More informationTHE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA, CV BoD in Egypt/ MENA
THE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA, CV BoD in Egypt/ MENA Prepared and presented by : Mahmoud Diaa Elmahdawy President, ISPOR Egypt s chapter
More informationCost-effectiveness Analysis for HHS
Cost-effectiveness Analysis for HHS Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID ASSIST Project, University Research Co., LLC Ukraine: 1 Mali: 1 Nigeria: 1 2 Uganda: 6 Burundi:
More informationThe DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN
1. INTRODUCTION The DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN 2014 2018 UNITE AGAINST DIABETES STOP RISING TREND Diabetes is a significant and growing challenge globally that affects individuals,
More informationCost-effectiveness analysis of a screening programme. Iris Lansdorp-Vogelaar, PhD Department of Public Health Erasmus MC, Rotterdam
Cost-effectiveness analysis of a screening programme Iris Lansdorp-Vogelaar, PhD Department of Public Health Erasmus MC, Rotterdam Criteria of Wilson and Jungner (Bull World Health Organ. 1968) Why cost-effectiveness
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationRADPAR WP 7: Cost-effectiveness
RADPAR WP 7: Cost-effectiveness May 2012: Final Report: Analysis of cost effectiveness and health benefits of radon control strategies Version 3 This publication arises from the project Radon Prevention
More informationEnhancing prevention and control of Rift Valley Fever in East Africa by intersectoral assessment of control options
Enhancing prevention and control of Rift Valley Fever in East Africa by intersectoral assessment of control options Tabitha Kimani, (MLD) Esther Schelling, (STI) Tom Randolph, (ILRI) Margaret Ngigi, (EU)
More informationEconomic Evaluations of Diet and Supplementation DR MICHELE SADLER, CONSULTANT NUTRITIONIST DIRECTOR, RANK NUTRITION LTD
Economic Evaluations of Diet and Supplementation DR MICHELE SADLER, CONSULTANT NUTRITIONIST DIRECTOR, RANK NUTRITION LTD Spending on health Growing population Ageing population next 15 years +4.4 million
More informationWHO Health Statistics : Applied through the lens of the Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases
WHO Health Statistics : Applied through the lens of the Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases Dr E Tursan d'espaignet Prevention of Noncommunicable Diseases
More informationDevelopment of a Regional Framework of Action in obesity Prevention in the Eastern Mediterranean Region
Development of a Regional Framework of Action in obesity Prevention in the Eastern Mediterranean Region Ayoub Al Jawaldeh; Regional Adviser, WHO- EMRO 2011 Political declaration on NCDs, Sustainable Development
More informationASIA-PACIFIC HEART HEALTH CHARTER
ASIA-PACIFIC HEART HEALTH CHARTER The Asia-Pacific Heart Health Charter has been developed by the Asia-Pacific Heart Network in collaboration with Asia Pacific Society of Cardiology to help stem the growing
More informationOptimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients
Optimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients Jennifer E. Mason PhD Student Edward P. Fitts Department of Industrial and Systems Engineering NC State University, Raleigh,
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
More informationNon communicable Diseases
Non communicable Diseases Vision, Goals and Challenges Where we are in Palestine? Dr. Johny R. Khoury Consultant Cardiologist Medical Relief Prevention and Diagnostic Center of cardiovascular diseases
More informationThe IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases
The IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases The International Atomic Energy Agency works to improve human health through the use of nuclear techniques. This includes
More informationSOUTH AFRICAN DECLARATION ON THE PREVENTION AND CONTROL OF NON-COMMUNICABLE DISEASES
SOUTH AFRICAN DECLARATION ON THE PREVENTION AND CONTROL OF NON-COMMUNICABLE DISEASES We, the participants in the South African Summit on the Prevention and Control of Non- Communicable diseases gathered
More informationSOUTH AFRICAN DECLARATION ON THE PREVENTION AND CONTROL OF NON-COMMUNICABLE DISEASES
SOUTH AFRICAN DECLARATION ON THE PREVENTION AND CONTROL OF NON-COMMUNICABLE DISEASES We, the participants in the South African Summit on the Prevention and Control of Non- Communicable diseases gathered
More informationEU support to hepatitis research. Anna Lönnroth Sjödén Health Research DG Research - European Commission
EU support to hepatitis research Anna Lönnroth Sjödén Health Research DG Research - European Commission Hepatitis B and C Summit, Brussels, 15 October 2010 1 Main Objectives: to improve quality of life
More informationAPPLICATION OF COST/BENEFIT ANALYSIS TO
APPLICATION OF COST/BENEFIT ANALYSIS TO NEW/EVOLVING FOOD TECHNOLOGIES Jason P.H. Jones, Ph.D. Senior Research Economist RTI International, Research Triangle Park, North Carolina IFT 2016, Chicago IL July
More informationChallenges and solutions in making evidence-based national vaccination policies and recommendations
Challenges and solutions in making evidence-based national vaccination policies and recommendations Philippe Duclos, WHO 15th ADVAC, Les Pensières, Veyrier du Lac, May 19, 2014 Developing evidence-based
More informationARGENTINE INITIATIVE TO REDUCE SODIUM CONSUMPTION Less Salt, More Life
ARGENTINE INITIATIVE TO REDUCE SODIUM CONSUMPTION Less Salt, More Life Background Salt consumption in Argentina is estimated to be 12-13 gr. per day/hab WHO and FAO recomends a daily salt consumption
More informationModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
More informationEconomic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women
Y O R K Health Economics C O N S O R T I U M NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women Supplementary Report
More informationAssessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model
Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is
More informationFRUIT AND VEGETABLES CONSUMPTION AND PREVENTION OF CHRONIC DIET-RELATED NON- COMMUNICABLE DISEASES. Mike Rayner Chair EHN Expert Group on Nutrition
British Heart Foundation Health Promotion Research Group FRUIT AND VEGETABLES CONSUMPTION AND PREVENTION OF CHRONIC DIET-RELATED NON- COMMUNICABLE DISEASES Mike Rayner Chair EHN Expert Group on Nutrition
More informationStudy population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.
Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis Parent du Chatelet I, Gessner B
More informationSession 6. Evaluating the Cost of Pharmaceuticals
Drug and Therapeutics Committee Training Course Session 6. Evaluating the Cost of Pharmaceuticals Trainer s Guide Drug and Therapeutics Committee Training Course Trainer s Guide This document was made
More informationDetermining the cost-effectiveness of mass screening for cervical cancer using common analytic models Sato S, Matunaga G, Tsuji I, Yajima A, Sasaki H
Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models Sato S, Matunaga G, Tsuji I, Yajima A, Sasaki H Record Status This is a critical abstract of an economic
More informationPanel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?
Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions? 2017 CADTH Symposium Ottawa, April, 24th, 2017 Reiner
More informationInternational model for prevention of chronic disease: Finland experience
International model for prevention of chronic disease: Finland experience Erkki Vartiainen, MD, Professor, Assistant Director General 06/12/2011 Erkki Vartiainen 1 2 Start of the North Karelia project
More informationThe prevalence, economic cost and research funding of dementia compared with other major diseases. Executive summary
DEMENTIA 2010 The prevalence, economic cost and research funding of dementia compared with other major diseases Executive summary A report produced by the Health Economics Research Centre, University of
More informationFilling Research Gaps to meet the Malnutrition Challenge : building evidences
1 Filling Research Gaps to meet the Malnutrition Challenge : building evidences 20th meeting of the EC-US Task Force on Biotechnology Research 3-4 June 2010, Barcelona Isabelle de Froidmont-Göertz Unit
More informationA cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationSaving lives and resources by preventing osteoporotic fractures with dairy products
Saving lives and resources by preventing osteoporotic fractures with dairy products CERIN-EMF-GDP LUNCH SYMPOSIUM Dr Mickael Hiligsmann, PhD Assistant Professor in Health Economics and Health Technology
More informationCost-Effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease
Linköping University Medical Dissertations No. 1011 Cost-Effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease Martin Henriksson Center for Medical Technology Assessment
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationExotic diseases approaching EU EFSA mandates on Peste des Petits Ruminants (PPR) and lumpy skin disease (LSD) coordinated by Alessandro Broglia
Exotic diseases approaching EU EFSA mandates on Peste des Petits Ruminants (PPR) and lumpy skin disease (LSD) coordinated by Alessandro Broglia Frank Verdonck Animal and Plant Health Unit European Food
More informationStuart Peacock. Cancer Control Research, BC Cancer Agency Canadian Centre for Applied Research in Cancer Control (ARCC) Simon Fraser University
Stuart Peacock Cancer Control Research, BC Cancer Agency Canadian Centre for Applied Research in Cancer Control (ARCC) Simon Fraser University Advancing Health Economics, Services, Policy and Ethics I
More informationExpert Models for Decision Makers TM Creme Global Reformulation Project under FDII s Health Strategy: Methodology
G L O B A L Expert Models for Decision Makers TM Creme Global Reformulation Project under FDII s Health Strategy: Methodology Dr. Aileen Connolly Dietary Intake Specialist 11 th September 2014 The Creme
More informationSource of effectiveness data The effectiveness evidence came from a review of published studies and the authors' assumptions.
Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond Tice J A, Ross E, Coxson P G, Rosenberg
More informationCost effectiveness of beta blocker therapy for patients. with chronic severe heart failure. in Ireland. M. Barry
IMJ June 2002;95(6):174-177 Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland M. Barry Irish National Centre for Pharmacoeconomics Address for correspondence
More informationThe Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting
The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic
More informationScotland Policy Conferences: Policy priorities for tackling obesity in Scotland
Scotland Policy Conferences: Policy priorities for tackling obesity in Scotland Assessing the strategy s potential to narrow health inequalities Dr David Blane Academic GP, Glasgow @dnblane Declaration
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More informationPolitical incentives for more effective prevention including health care settings
Pekka Puska, MD, PhD, MpolSc Ex director General, National Institute for Health and Welfare (THL), Finland President, Int. Association of National Public Health Institutes (IANMPHI) Political incentives
More informationThe European Neighbourhood Policy (ENP) ENP Coordination External Relations Directorate General European Commission
The European Neighbourhood Policy (ENP) ENP Coordination External Relations Directorate General European Commission Different neighbours, different relations EFTA / EEA Candidate Countries (Croatia, former
More informationMethodological requirements for realworld cost-effectiveness assessment
Methodological requirements for realworld cost-effectiveness assessment Ismo Linnosmaa Department of Health and Social Management, UEF Centre for Health and Social Economics, THL Ismo Linnosmaa Outline
More informationb de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY
b de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY Human papillomaviruses (HPV) are common sexually transmitted viruses. They can cause several types
More informationGeneralised cost-effectiveness analysis for breast cancer prevention and care in Hong Kong Chinese. Wong, IOL; Tsang, JWH; Cowling, BJ; Leung, GM
Title Generalised cost-effectiveness analysis for breast cancer prevention and care in Hong Kong Chinese Author(s) Wong, IOL; Tsang, JWH; Cowling, BJ; Leung, GM Citation Hong Kong Medical Journal, 2015,
More informationOHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee
OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension Ontario Health Technology Advisory Committee May 2012 Background Hypertension in Canada Hypertension occurs when
More informationSaving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH)
1 Saving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH) Economics Chapter: Estimating the benefits from treatment and increasing
More informationHow to evaluate the economic impact of interventions I: introduction and costing analyses
How to evaluate the economic impact of interventions I: introduction and costing analyses Raymond Hutubessy Initiative for Vaccine Research (IVR), Geneva, Switzerland Mark Jit WHO consultant, Health Protection
More informationCost-effectiveness of spironolactone in patients with severe heart. failure
IJMS 2003;172(2):70-72 Cost-effectiveness of spironolactone in patients with severe heart failure Tilson L, McGowan B, Ryan M, Barry M Correspondence to: Dr.Michael Barry. National Centre for Pharmacoeconomics,
More informationTIPI di ANALISI ECONOMICHE Patrizia Berto LASER Analytica - Milano
TIPI di ANALISI ECONOMICHE Patrizia Berto LASER Analytica - Milano 1 DIFFERENCE BETWEEN COST-CONTAINMENT AND COST-OPTIMIZATION Prices & volumes control Co-payments Control on prescriptions Allocation of
More informationSeventh Session of OIC-StatCom
Seventh Session of OIC-StatCom 2 3 May 2018, Ankara- Session on Implemented Activities of the OIC-StatCom Progress Report on Integration of the Tobacco Questions for Surveys (TQS) into the National Surveys
More informationWHO Secretariat Dr Timothy Armstrong Coordinator, Surveillance and Population-based Prevention Department of Chronic Diseases and Health Promotion
WHO Secretariat Dr Timothy Armstrong Coordinator, Surveillance and Population-based Prevention Department of Chronic Diseases and Health Promotion Overview: Revised WHO Discussion Paper (A/NCD/INF./1)
More informationGlobal NCD Prevention WHO Strategies and Implementation Plan. Dr Ruitai Shao Chronic Disease and Health Promotion
Global NCD Prevention WHO Strategies and Implementation Plan Dr Ruitai Shao Chronic Disease and Health Promotion Outline Main NCDs and Major risk factors Global Action Plan for implementing the strategy
More informationExotic diseases approaching EU EFSA mandates on PPR, sheep pox, lumpy skin disease
Exotic diseases approaching EU EFSA mandates on PPR, sheep pox, lumpy skin disease Frank Verdonck Animal and Plant Health Unit European Food Safety Authority - EFSA PAFF meeting -13-14 Jan 2015 BACKGROUND
More informationThe cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S Record Status This is a critical abstract of an economic evaluation
More informationEconomically efficient approaches to address chronic disease in developing countries
Economically efficient approaches to address chronic disease in developing countries Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Brigham & Women s Hospital Harvard Medical School Center
More informationBrain research supported by the European Union
Brain research supported by the European Union Lara Passante, PhD Health Directorate Directorate-General for Research & European Commission FENS Featured Regional Meeting 11-14 Septembre 2013 Prague Neuroscience:
More informationThe cost-effectiveness of omega-3 supplements for prevention of secondary coronary events Schmier J K, Rachman N J, Halpern M T
The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events Schmier J K, Rachman N J, Halpern M T Record Status This is a critical abstract of an economic evaluation that
More informationOverview of the Global NCD Action Plan
Regional Consultation to Develop the Strategic Action Plan and Targets for Prevention and Control of Noncommunicable Diseases in the SEAR 25-27 February 2013 Overview of the Global NCD Action Plan 2013-2020
More informationAppendix. Background Information: New Zealand s Tobacco Control Programme. Report from the Ministry of Health
Appendix Background Information: New Zealand s Tobacco Control Programme Report from the Ministry of Health April 2016 1 Contents The cost of smoking to individuals and society... 3 What impact is New
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Cleland J G F, Takala A, Apajasalo M,
More informationThe cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E
The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationWHO Draft Guideline: Sugars intake for adults and children. About the NCD Alliance. Summary:
WHO Draft Guideline: Sugars intake for adults and children About the NCD Alliance The NCD Alliance is a unique civil society network of over 2,000 organizations in more than 170 countries focused on raising
More informationHypertension in the South-East Asia Region: an overview
Hypertension in the South-East Asia Region: an overview Anand Krishnan i, Renu Garg ii and Athula Kahandaliyanage iii Abstract Raised blood pressure or hypertension is the single most important risk factor
More informationThe Cost of Overweight and Obesity on the Island of Ireland
t The Cost of Overweight and Obesity on the Island of Ireland Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. JANPA Launch- WP 4 Meeting September 2015 Acknowledgements
More informationHealthcare expenditure and productivity cost savings resulting from increased intake of grain fibre in Australia.
Healthcare expenditure and productivity cost savings resulting from increased intake of grain fibre in Australia. WHITE PAPER ACKNOWLEDGEMENT Kellogg Australia commissioned Nutrition Research Australia
More informationNew Delhi Declaration
New Delhi Declaration on High Blood Pressure Thirty-first Meeting of Ministers of Health of Countries of the WHO South-East Asia Region 10 September 2013, New Delhi, India We, the Health Ministers of
More informationMedia centre Obesity and overweight
1 of 5 06/05/2016 4:54 PM Media centre Obesity and overweight Fact sheet N 311 Updated January 2015 Key facts Worldwide obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults,
More informationPharmacoeconomics: from Policy to Science. Olivia Wu, PhD Health Economics and Health Technology Assessment
Pharmacoeconomics: from Policy to Science Olivia Wu, PhD Health Economics and Health Technology Assessment Potential conflicts of interest - none 2 Pharmacoeconomics: from policy to science - Why the need
More informationNicotine replacement therapy to improve quit rates
Nicotine replacement therapy to improve quit rates Matrix Insight, in collaboration with Imperial College London, Kings College London and Bazian Ltd, were commissioned by Health England to undertake a
More informationInnovative or good practices, projects or programmes on preventing drinking and driving and the consequences of drinking and driving
Innovative or good practices, projects or programmes on preventing drinking and driving and the consequences of drinking and driving The purpose of this task is to build up a database of examples of practices,
More informationBest practices of Members States on Food reformulation. results from trio questionnaire 2016
Best practices of Members States on Food reformulation results from trio questionnaire 216 I. Trusková et al. Public Health Authority of SR Ministry of Health of SR Food reformulation Food reformulation
More informationFuture of health workforce education for addressing NCDs in the global health context - WHO perspectives
18/10/2018 1 Future of health workforce education for addressing NCDs in the global health context - WHO perspectives Dr Benoit VARENNE, DDS, MPH, PhD Dental Officer, WHO HQ Geneva 23 rd CONGRESS EADPH,
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationA logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool
EUREGIO III A logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool PURPOSE OF A HEALTH SERVICE To utilise resources allocated to the health
More informationTitle of the presentation
. Title of the presentation Economic analyses for hepatitis elimination Subtitle of the presentation, lorem ipsum dolor sit amet. Yvan Hutin, Global Hepatitis Programme, World Health Organization November
More informationFACTS FIGURES A FUTURE
International Agency for Research on Cancer, 2012 Let s face the ACTS GLOBAL INITIATIVE FOR CANCER REGISTRY DEVELOPMENT INITIATIVE MONDIALE POUR LE DEVELOPPEMENT DES REGISTRES DU CANCER INICIATIVA MUNDIAL
More informationCYPRUS PRESIDENCY OF THE COUNCIL OF THE EU
CYPRUS PRESIDENCY OF THE COUNCIL OF THE EU July December 2012 Research Symposium on Digestive and Liver Diseases Brussels, 18 September 2012 Dr Myrto Azina- Chronides Ministry of Health Cyprus Digestive
More informationDiabetes. Halt the diabetes epidemic
Diabetes Halt the diabetes epidemic WHO Library Cataloguing in Publication Data World Health Organization. Regional Office for the Eastern Mediterranean Diabetes: halt the diabetes epidemic / World Health
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationDates to which data relate The dates of the effectiveness and resource use data were not reported. The price year was 2000.
Cost-effectiveness of spa treatment for fibromyalgia: general health improvement is not for free Zijlstra T R, Braakman-Jansen L M, Taal E, Rasker J J, van de Laar M A Record Status This is a critical
More information